Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Troxatyl

 
National Institutes of Health

Related topics

Related topics

2 relations
BCH 4556

Broader (1)

troxacitabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer
BackgroundGemcitabine, a deoxycytidine nucleoside analog, is the current standard chemotherapy used as first-line treatment for… Expand
  • table 1
  • table 3
  • table 4
  • figure 2
  • figure 3
Is this relevant?
2004
2004
Action of Troxacitabine on Cells Transduced with Human Cytidine Deaminase cDNA
Troxacitabine (β-L-Dioxolane-cytidine; Troxatyl™) is a β-L-nucleoside analog, which has shown preclinical antitumor activity in… Expand
Is this relevant?
2003
2003
Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells
PurposeTroxacitabine (BCH-4556, l-(−)-OddC, Troxatyl) is a novel β-l-nucleoside analogue with potent antineoplastic activity both… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2003
2003
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
PURPOSE A multi-institution phase II study was undertaken by National Cancer Institute of Canada-Clinical Trials Group to… Expand
Is this relevant?
2003
2003
Troxacitabine: BCH 4556, SPD 758, Troxatyl.
  • Drugs in R&D
  • 2003
    • Corpus ID: 22278267
Troxacitabine [BCH 4556; SPD 758; Troxatyl] is a DNA synthesis inhibitor. This profile has been selected from R&D Insight, a… Expand
Is this relevant?
2002
2002
Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts
Abstract Purpose. We have recently identified a deoxycytidine nucleoside analogue, troxacitabine (β-L-dioxolane cytidine… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2002
2002
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
PURPOSE Troxacitabine (Troxatyl, BCH-4556; BioChem Pharma Inc, Basingstoke, United Kingdom) is a novel synthetic L-nucleoside… Expand
Is this relevant?
Review
2002
Review
2002
Troxacitabine-based therapy of refractory leukemia
Unique among currently approved or in-development nucleoside analogs, troxacitabine (Troxatyl™) is an L-nucleoside with… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Troxacitabine (Troxatyl; BCH-4556; (-)-2'-deoxy-3'-oxacytidine), a deoxycytidine analogue with an unusual dioxolane structure and… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2000
2000
Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity
Abstract.Purpose: Troxacitabine (β-L-dioxolane cytidine, BCH-4556; Troxatyl, BioChem Pharma Inc.) is a novel nucleoside analogue… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE